hello all IMMMULOGICians:
while I am unhappy to see IMUL setback due to bureaucratic snafu and I am certain its share price will suffer today and in the near term, one should be aware of the setback is only the ragweed trial, albeit it is a major segment within its Allervax pgm (~20 mil ragweed sufferers.) Phase II of the Cat allergy pgm will continue. Additionally, while its mgt is trying to concentrate on Allervax, its COCAINE and MS pgms are not dead yet. According to the local paper, IMUL still has $63M. Does anyone know what is the burnt rate, especially after its cost (job) cutting efforts?
personally, I think it is equally important, if not more so, if IMUL can find a credible corporate sponsor. As we may well aware, the losing of H.M.D. is a serious blow.
regards, Bosco |
